SCHEMBL25544936

SCHEMBL25544936

CCOC(=O)c1cc(C(=O)c2sc(N(c3ccc(F)cc3)C(C)C(N)=O)nc2N)on1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.39
KDM4E B2RXH2 5/20 0.39
NPC1 O15118 4/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 5/20 0.38
LMNA P02545 4/20 0.38
TP53 P04637 3/20 0.37
TRPM8 Q7Z2W7 1/20 0.37
DHODH Q02127 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
POLB P06746 1/20 0.35
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
HPGD P15428 3/20 0.34
MAPK1 P28482 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
PKM P14618 1/20 0.34
NFKB1 P19838 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30210926 1.00 MAPT (0.39) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL30211003 0.97 MAPT (0.36) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL30210843 0.94 KDM4E (0.47) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL23930595 0.88 CCNA2 (0.37) MAPTNPC1SMN1; SMN2LMNATP53
SCHEMBL31633436 0.88 CCNA2 (0.37) MAPTNPC1SMN1; SMN2LMNATP53
SCHEMBL23930498 0.86 MAPT (0.38) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL30210848 0.86 MAPT (0.38) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL30437290 0.85 MAPT (0.37) MAPTNPC1SMN1; SMN2LMNATP53
SCHEMBL23930496 0.85 MAPT (0.37) MAPTNPC1SMN1; SMN2LMNATP53
SCHEMBL23930565 0.84 MAPT (0.35) MAPTNPC1LMNATP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 CN claimed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG MAPT 3251/4885KDM4E 1128/4885NPC1 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.